eResearchTechnology and Mortara Instrument Enter into a Strategic Alliance to Provide Enhanced Digital ECG Products and Services
28 July 2005 - 7:10AM
PR Newswire (US)
eResearchTechnology and Mortara Instrument Enter into a Strategic
Alliance to Provide Enhanced Digital ECG Products and Services
Agreement to Provide eRT with a Virtual Manufacturing Partner; eRT
will Market Proprietary Products to Global Drug Developers
PHILADELPHIA, July 27 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), (NASDAQ:ERES), a leading provider
of centralized electrocardiographic (ECG) collection and
interpretation services, announced today a strategic agreement with
Mortara Instrument, Inc., a leading provider of ECG technologies
and architect of the E-Scribe ECG Warehouse designed for the United
States Food and Drug Administration ("FDA") Center for Drug
Evaluation and Research. The agreement includes production of an
eRT branded digital ECG collection device, appoints eRT as the
exclusive ECG core laboratory reseller of Mortara's E-Scribe ECG
Warehouse Services, and designates eRT an authorized reseller of
Mortara collection devices to the global drug development industry.
Key details of this comprehensive agreement include: -- Production
of an eRT private label digital ECG collection device based on the
new Mortara ELI 150 Rx 12-lead resting ECG technology platform. eRT
will be first to market with an ELI 150 Rx-based solution, which
features an advanced design optimized for clinical research. The
agreement provides a mechanism for close design and engineering
collaboration between eRT and Mortara to drive ongoing improvements
to the eRT private label digital ECG collection platform, including
tight integration with eRT's EXPeRT(R) workflow enabled data
handling technology, the first solution in production that was
designed explicitly to meet emerging international regulatory
guidance and technical standards. The eRT private label line will
be available in the fourth quarter. -- Designation of eRT as an
authorized reseller of Mortara digital ECG collection devices to
the global drug development industry. eRT will serve as a
fulfillment channel for demand from the global drug development
community to purchase or rent Mortara digital ECG collection
devices. In addition, eRT will work with sponsors that have
selected eRT to perform ECG core laboratory services and prefer to
purchase digital ECG collection devices from eRT as opposed to
renting units on a trial-by-trial basis. eRT will offer equipment
purchasers its industry leading site support and logistics
services, including dedicated warehouse and repair/replacement
services. -- Designation of eRT as the exclusive ECG core
laboratory reseller of Mortara's E-Scribe ECG Warehouse Services.
With the addition of Mortara's E-Scribe ECG Warehouse Services, eRT
will be able to offer drug developers full lifecycle solutions that
include the ability for sponsors to view and manage annotated ECGs
as well as to proactively review ECG waveforms for significant
outliers utilizing the Mortara toolset designed specifically for
the FDA review process. The identification of outliers will be made
by scoring algorithms developed by Mortara under a Cooperative
Research and Development Agreement (CRADA) with the FDA executed in
June 2004 to create the digital ECG warehouse. "This landmark
agreement brings several sustainable competitive advantages to eRT
and its customers that will drive better outcomes for cardiac
safety services in new drug development and reinforces eRT's global
industry leadership in technology, capability and capacity to meet
growing demand," said Scott Grisanti, senior vice president of
business development and chief marketing officer at eRT. "First,
availability of an eRT branded digital ECG collection device will
allow eRT to enjoy scale economies that support our ongoing
strategy to deliver best value to our customers and continuously
raise the bar for service through tighter integration between
digital ECG collection and eRT's EXPeRT(R) processing platform.
Second, the authorized reseller arrangement allows eRT to assist
drug developers to implement new strategies that institutionalize
digital ECG collection and central processing across all phases of
clinical research. "Further, being named exclusive ECG core
laboratory reseller of the Mortara E-Scribe ECG Warehouse will
ensure that this cutting edge solution delivers optimal market
value by leveraging the global reach of eRT's consultative business
development organization. Also, the reseller arrangement builds on
earlier collaboration between eRT, Mortara, and A.M.P.S., LLC
(AMPS) on the development of the standard, annotated digital ECG
submission format used as the foundation of the Warehouse.
Executives from eRT, Mortara and AMPS were recognized for their
collaboration on the digital ECG waveform standard with an FDA
Commissioner's Special Citation in 2003." Dr. Justin L. Mortara,
vice president of Mortara Instrument commented, "This strategic
agreement between eRT and Mortara offers substantial value to the
drug development community by combining Mortara's leadership in the
design and delivery of the premier digital ECG collection platform
for use in clinical research with eRT's global reach and market
presence. The agreement demonstrates Mortara's understanding of the
unique requirements of ECG central laboratories and a willingness
to develop solutions for their specific needs. It also establishes
a foundation for collaborative research and development between the
organizations that will allow ongoing optimization of Mortara's
technology by channeling feedback from eRT's unmatched experience
and customer base in the clinical trials arena. eRT's role as the
E-Scribe ECG Warehouse reseller will complement Mortara's direct
ECG Warehouse service offering and allow the industry to derive
maximum benefit in choosing digital ECG technologies to expedite
the new drug candidate review and approval process." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Based in Milwaukee, WI, Mortara
Instrument, Inc. is distinguished in the field of non-invasive
cardiology for innovations that are the core of the company's
complete line of ECG products including electrocardiographs, stress
exercise systems, Holter systems, data warehousing solutions, and
cardiology monitoring systems. The company's website is
http://www.mortara.com/. Statements included in this release may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development and market demand. As a result,
actual results may differ materially from any financial outlooks
stated herein. Further information on potential factors that could
affect the company's financial results can be found in the
company's Reports on Forms 10- K and 10-Q filed with the Securities
and Exchange Commission. DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci, eResearchTechnology, Inc.,
+1-908-203-6473, or Matt Hayden, Hayden Communications,
+1-858-704-5065, for eResearchTechnology Web site:
http://www.mortara.com/ Web site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024